Peri -and Postoperative Drug Therapy Schedules for Morbidly Obese Patients (POP-II)
Primary Purpose
Obese, Atracurium, Cefazolin
Status
Completed
Phase
Phase 4
Locations
Netherlands
Study Type
Interventional
Intervention
Atracurium, TBW
Sponsored by

About this trial
This is an interventional diagnostic trial for Obese focused on measuring Obese, Atracurium, Cefazolin, Morfine, Nadroparin
Eligibility Criteria
Inclusion Criteria:
- Morbidly obese patients undergoing bariatric surgery with a BMI > 40 kg/m2, ASA I-III
Exclusion Criteria:
- Epilepsy, pregnancy, breastfeeding and known allergy allergies to cefazolin, morphine, nadroparin, atracurium, or benzene sulphonic acid. History of coagulation disorder or history of heparin/LMWH induced thrombocytopenia.
Sites / Locations
- St. Antonius Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Atracurium, TBW
Atracurium IBW
Arm Description
Dose of atracurium 0.5 mg/kg based on total body weight
dose 0.5 mg/kg based on ideal body weight
Outcomes
Primary Outcome Measures
Time course of the pharmacodynamic effect of atracurium
Pharmacokinetic parameters of cefazolin in blood
Pharmacokinetic parameters of morphine and metabolites in blood
Time course of anti-factor Xa levels in blood following nadroparin
Secondary Outcome Measures
Dosing of atracurium based on total or ideal body weight
To compare primary endpoints (obtained in morbidly obese patients) with data of non-obese patients
The occurrence of postoperative wound infections
Postoperative pain scores, sedation scores and nausea scores
The occurrence of bleedings or thrombotic events
Required amounts of morphine (PCA)
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01097148
Brief Title
Peri -and Postoperative Drug Therapy Schedules for Morbidly Obese Patients
Acronym
POP-II
Official Title
Peri -and Postoperative Drug Therapy Schedules for Morbidly Obese Patients
Study Type
Interventional
2. Study Status
Record Verification Date
November 2009
Overall Recruitment Status
Completed
Study Start Date
November 2009 (undefined)
Primary Completion Date
April 2010 (Actual)
Study Completion Date
April 2010 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
St. Antonius Hospital
4. Oversight
5. Study Description
Brief Summary
Rationale: Obesity is an increasing health risk worldwide, with the USA recording prevalence in adults of around 20%. The mean body weight of obese patients is also increasing. One of the strategies to treat extreme obesity (Body Mass Index (BMI) > 40 kg/m2) is weight-reducing surgery like laparoscopic gastric banding or gastric bypass. During anaesthesia, morbidly obese patients are exposed to an increased risk at developing postoperative wound infections, apnoea and thrombotic events and may be more difficult to intubate. Routinely, amongst others, cefazolin, morphine, nadroparin and atracurium are administered in standard dosages. However, it is not known to what extend the pharmacokinetics and/or -dynamics of these drugs are affected in morbidly obese patients. Therefore, evidence-based dosing schedules for these drugs in morbidly obese patients should be developed.
Objective: The study is performed in order to develop population pharmacokinetic and/or pharmacodynamic models of the routinely used drug therapies during bariatric surgery in morbidly obese patients (BMI > 40 kg/m2): cefazolin, morphine, nadroparin and atracurium.
A covariate analysis will be performed in order to account for variability in pharmacokinetic and/or pharmacodynamic parameters. This covariate analysis will take into account procedure and patient bound covariates, with specific interest for body weight as a covariate. Whenever possible, non-obese patients will be included in the covariate analysis.
The results will be used to develop individualised dosing schemes for routinely used drugs peri-operatively in morbidly obese patients.
Study design: A randomised, prospective, observational, therapeutic and invasive study.
Study population: Morbidly obese patients with a Body Mass Index > 40 kg/m2 undergoing laparoscopic banding or gastric bypass surgery, 18-60 years old. A total of 20 patients will be included in the study.
Intervention (if applicable): All measurements and data collection will take place around administration of drugs that are given according to routine clinical practice (cefazolin 2 grams for prophylaxis of infections, morphine 10 mg intravenously at the end of surgery, a patient-controlled analgesia (PCA) pump with morphine for postoperative pain relief and nadroparin 0,6 ml for trombo-embolic prophylaxis). For muscle relaxation, patients are randomised to receive one of two generally accepted dosing regimen of atracurium (0.5 mg/kg based on ideal body weight or 0.5 mg/kg based on total body weight). Peri- and postoperatively, a maximum amount of 70 ml of blood will be collected from an indwelling arterial line for measurement of concentrations of cefazolin, morphine, and anti-Xa (nadroparin). One week after surgery the patient will be checked for thrombosis using ultrasonography.
Main study parameters/endpoints:
Primary endpoints to evaluate in morbidly obese patients are;
pharmacokinetic parameters of cefazolin in blood;
pharmacokinetic parameters of morphine and metabolites in blood;
time course of anti-factor Xa levels in blood following nadroparin;
time course of the pharmacodynamic effect of atracurium.
Secondary endpoints to evaluate in morbidly obese patients are:
to compare primary endpoints (obtained in morbidly obese patients) with data of non-obese patients
the occurrence of postoperative wound infections;
postoperative pain scores, sedation scores and nausea scores;
the occurrence of bleedings or thrombotic events ;
required amounts of morphine (PCA);
to compare the time course of the pharmacodynamic effect of two different doses of atracurium.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obese, Atracurium, Cefazolin, Morphine, Nadroparin
Keywords
Obese, Atracurium, Cefazolin, Morfine, Nadroparin
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
20 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Atracurium, TBW
Arm Type
Active Comparator
Arm Description
Dose of atracurium 0.5 mg/kg based on total body weight
Arm Title
Atracurium IBW
Arm Type
Active Comparator
Arm Description
dose 0.5 mg/kg based on ideal body weight
Intervention Type
Drug
Intervention Name(s)
Atracurium, TBW
Intervention Description
Dose atracurium 0.5 mg/kg based on total body weight
Primary Outcome Measure Information:
Title
Time course of the pharmacodynamic effect of atracurium
Time Frame
6 months
Title
Pharmacokinetic parameters of cefazolin in blood
Time Frame
6 months
Title
Pharmacokinetic parameters of morphine and metabolites in blood
Time Frame
6 months
Title
Time course of anti-factor Xa levels in blood following nadroparin
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Dosing of atracurium based on total or ideal body weight
Time Frame
6 months
Title
To compare primary endpoints (obtained in morbidly obese patients) with data of non-obese patients
Time Frame
6 months
Title
The occurrence of postoperative wound infections
Time Frame
6 months
Title
Postoperative pain scores, sedation scores and nausea scores
Time Frame
6 months
Title
The occurrence of bleedings or thrombotic events
Time Frame
6 months
Title
Required amounts of morphine (PCA)
Time Frame
6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Morbidly obese patients undergoing bariatric surgery with a BMI > 40 kg/m2, ASA I-III
Exclusion Criteria:
Epilepsy, pregnancy, breastfeeding and known allergy allergies to cefazolin, morphine, nadroparin, atracurium, or benzene sulphonic acid. History of coagulation disorder or history of heparin/LMWH induced thrombocytopenia.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Simone van Kralingen, MD
Organizational Affiliation
St. Antonius Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
St. Antonius Hospital
City
NIeuwegein
ZIP/Postal Code
3435EM
Country
Netherlands
12. IPD Sharing Statement
Citations:
PubMed Identifier
28510797
Citation
de Hoogd S, Valitalo PAJ, Dahan A, van Kralingen S, Coughtrie MMW, van Dongen EPA, van Ramshorst B, Knibbe CAJ. Influence of Morbid Obesity on the Pharmacokinetics of Morphine, Morphine-3-Glucuronide, and Morphine-6-Glucuronide. Clin Pharmacokinet. 2017 Dec;56(12):1577-1587. doi: 10.1007/s40262-017-0544-2.
Results Reference
derived
PubMed Identifier
25304008
Citation
Diepstraten J, Janssen EJ, Hackeng CM, van Dongen EP, Wiezer RJ, van Ramshorst B, Knibbe CA. Population pharmacodynamic model for low molecular weight heparin nadroparin in morbidly obese and non-obese patients using anti-Xa levels as endpoint. Eur J Clin Pharmacol. 2015 Jan;71(1):25-34. doi: 10.1007/s00228-014-1760-4. Epub 2014 Oct 12.
Results Reference
derived
Learn more about this trial
Peri -and Postoperative Drug Therapy Schedules for Morbidly Obese Patients
We'll reach out to this number within 24 hrs